Clinical Trial Update: A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000® [Phase 3]

View source ↗

Summary

A Phase 3 non-inferiority trial comparing MVA-BN Smallpox vaccine to ACAM2000 in vaccinia-naïve adults 18-42; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Smallpox

Drugs mentioned

• ACAM2000 (Vaccinia vaccine (live, cell culture-derived))
• MVA-BN Smallpox vaccine (Modified Vaccinia Ankara-Bavarian Nordic)

Snippet

Sponsor: Bavarian Nordic | Conditions: 18-42 Year Old Healthy Vaccinia-naïve Subjects | Phase 3 | Status: COMPLETED | Results posted: 2019-12-05